Accord Healthcare Ireland launch ORGOVYX®▼ (relugolix 120 mg) — oral androgen deprivation therapy for prostate cancer

Accord Healthcare Ireland launch ORGOVYX®▼ (relugolix 120 mg) — oral androgen deprivation therapy for prostate cancer

Accord Healthcare has launched its latest oncology treatment, ORGOVYX®▼ (relugolix) 120 mg which comes in pack size of 30 film-coated tablets.  Relugolix is the first and only oral androgen deprivation therapy (ADT) for advanced hormone-sensitive prostate cancer.
Accord Healthcare Ireland launch ORGOVYX®▼ (relugolix 120 mg) — oral androgen deprivation therapy for prostate cancer

Table of Contents

Share it with your colleagues

Facebook
Pinterest
Twitter
LinkedIn
WhatsApp
Print

IPU

Members Login